[go: up one dir, main page]

EA200300226A1 - GEM-SUBSTITUTED ANTAGONISTS INTEGRINE αvβ3 - Google Patents

GEM-SUBSTITUTED ANTAGONISTS INTEGRINE αvβ3

Info

Publication number
EA200300226A1
EA200300226A1 EA200300226A EA200300226A EA200300226A1 EA 200300226 A1 EA200300226 A1 EA 200300226A1 EA 200300226 A EA200300226 A EA 200300226A EA 200300226 A EA200300226 A EA 200300226A EA 200300226 A1 EA200300226 A1 EA 200300226A1
Authority
EA
Eurasian Patent Office
Prior art keywords
integrine
αvβ3
gem
antagonists
substituted
Prior art date
Application number
EA200300226A
Other languages
Russian (ru)
Inventor
Иш Кумар Кханна
И Юй
Хуан Фаньлу
Низал С. Чандракумар
Рени М. Хафф
Марк А. Расселл
Марк Л. Бойз
Лори А. Шретцман
Барбара Б. Чэнь
Бипинчандра Н. Десай
Сринивасан Радж Нагараджан
Алан Ф. Газики
Томас Д. Пеннинг
Томас Роджерс
Джон Адам Уендт
Алберт Килевич
Япин Ван
Original Assignee
Фармасиа Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармасиа Корпорейшн filed Critical Фармасиа Корпорейшн
Publication of EA200300226A1 publication Critical patent/EA200300226A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к классу соединений, представленных формулой (I)или к их фармацевтически приемлемым солям, к фармацевтическим композициям, включающим соединения формулы (I), и к способам селективного ингибирования интегрина αβи/или αβили антагонистического воздействия на интегрин αβи/или αβ.Международная заявка была опубликована вместе с отчетом о международном поиске.The present invention relates to a class of compounds represented by formula (I) or to their pharmaceutically acceptable salts, to pharmaceutical compositions comprising compounds of formula (I), and to methods for selectively inhibiting integrin αβ and / or αβ or antagonistic effect on integrin αβ and / or αβ.International The application was published with the international search report.

EA200300226A 2000-08-30 2001-08-29 GEM-SUBSTITUTED ANTAGONISTS INTEGRINE αvβ3 EA200300226A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22918600P 2000-08-30 2000-08-30
PCT/US2001/026963 WO2002018340A1 (en) 2000-08-30 2001-08-29 GEM-SUBSTITUTED α v β 3 INTEGRIN ANTAGONISTS

Publications (1)

Publication Number Publication Date
EA200300226A1 true EA200300226A1 (en) 2003-10-30

Family

ID=22860154

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300226A EA200300226A1 (en) 2000-08-30 2001-08-29 GEM-SUBSTITUTED ANTAGONISTS INTEGRINE αvβ3

Country Status (16)

Country Link
EP (1) EP1313705A1 (en)
JP (1) JP2004510708A (en)
KR (1) KR20030027106A (en)
CN (1) CN1471512A (en)
AU (1) AU2001288515A1 (en)
BR (1) BR0113671A (en)
CA (1) CA2419699A1 (en)
CZ (1) CZ2003459A3 (en)
EA (1) EA200300226A1 (en)
IL (1) IL154496A0 (en)
MX (1) MXPA03001759A (en)
NO (1) NO20030925L (en)
NZ (1) NZ524159A (en)
PL (1) PL365729A1 (en)
WO (1) WO2002018340A1 (en)
ZA (1) ZA200301162B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1653970A4 (en) * 2003-08-13 2008-10-15 Novartis Vaccines & Diagnostic GSK-3 INHIBITORS AND USES
MX2007004535A (en) * 2004-10-14 2007-06-08 Pharmacia Corp Biphenyl integrin antagonists.
CN101880270B (en) * 2009-05-07 2012-10-03 上海华升生物科技有限公司 Method for preparing 1,1-cyclopropanedimethyl cyclicsulfite
EP3929196B1 (en) 2013-09-24 2023-08-23 FUJIFILM Corporation Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof
KR20220102669A (en) * 2019-10-16 2022-07-20 모픽 테라퓨틱, 인코포레이티드 Inhibition of human integrin α4β7

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
CZ203898A3 (en) * 1995-12-29 1999-03-17 Smithkline Beecham Corporation Antagonist of vitronectin receptor, pharmaceutical composition containing thereof, process of its preparation and use
US5919792A (en) * 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
CA2297910A1 (en) * 1997-07-25 1999-02-04 Smithkline Beecham Corporation Vitronectin receptor antagonist
CA2303846A1 (en) * 1997-09-24 1999-04-01 Smithkline Beecham Corporation Vitronectin receptor antagonist

Also Published As

Publication number Publication date
NZ524159A (en) 2004-08-27
EP1313705A1 (en) 2003-05-28
JP2004510708A (en) 2004-04-08
AU2001288515A1 (en) 2002-03-13
WO2002018340A1 (en) 2002-03-07
CN1471512A (en) 2004-01-28
KR20030027106A (en) 2003-04-03
CZ2003459A3 (en) 2003-09-17
PL365729A1 (en) 2005-01-10
BR0113671A (en) 2004-01-06
MXPA03001759A (en) 2004-11-01
NO20030925D0 (en) 2003-02-27
ZA200301162B (en) 2004-05-12
NO20030925L (en) 2003-04-24
CA2419699A1 (en) 2002-03-07
IL154496A0 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
EA200300919A1 (en) N-SUBSTITUTED NON-ARYL HETEROCYCLIC ANTAGONISTS NMDA / NR2B
EA200201179A1 (en) DERIVATIVES 2-AMINOKARBONIL-9H-PURINA
EA200200938A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DERIVATIVES OF AZETIDINE, NEW DERIVATIVES OF AZETIDINE AND THEIR RECEIVING
HRP20080666T3 (en) Cgrp receptor antagonists
CY1106522T1 (en) ETEOCYCLIC COMPOUND AND ANTICANCER AGENT CONTAINING THE SAME AS AN ACTIVE INGREDIENT
ATE212978T1 (en) PARA-SUBSTITUTED PHENYLPROPANE ACID DERIVATIVES AS INTEGRIN ANTAGONISTS
DK0765314T3 (en) Benzoheterocyclic derivatives which can be used as vasopressin or oxytocin modulators
EA200300050A1 (en) GLYKOPEPTIDPHOSPHONATE DERIVATIVES
ATE283253T1 (en) SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES AS LXR AGONISTS
BG66085B1 (en) Phenylalanine derivatives
DE602004008098D1 (en) SUBSTITUTED 2H-Ä1,2,4ÜTRIAZOLOÄ4,3-AÜPYRAZINE AS GSK-3 INHIBITORS
WO2001096334A3 (en) Heteroarylalkanoic acids as integrin receptor antagonists
TR200102489T2 (en) 3-Phenylpyridine Derivatives and their use as NK-1 receptor antagonists
UY26780A1 (en) CYCLALQUIL AVB3 ANTAGONISTS
DE60230127D1 (en) INHIBITORS OF INTEGRIN ALPHA-V-BETA-6
ATE377602T1 (en) MORPHINAN DERIVATIVES AND THEIR MEDICAL APPLICATIONS
ATE374190T1 (en) TETRAHYDROQUINAZOLINE DERIVATIVES AS CFR ANTAGONISTS
EA200300593A1 (en) PIPERASINYLPIRASIN COMPOUNDS AS AGONISTS OR ANTAGONISTS OF SEROTONIN 5-HT2 RECEPTOR
EA200400140A1 (en) ORAL ANTI-DIABETIC AGENTS
EA200400467A1 (en) 3-AZABICYCLO (3.1.0) DERIVATIVES OF HEXANE AS ANTAGONISTS OPIOID RECEPTOR
EA200300629A1 (en) CONDENSED DERIVATIVES OF PURIN AS ANTAGONISTS OF Adenosine A receptors
HRPK20040372B3 (en) Crystalline sodium salt of telmisartan and the use of the same as an angiotensin antagonist
BRPI0406704A (en) 5ht ~ 7 ~ Antagonists and Inverse Agonists
EA200100517A1 (en) ANTAGONISTS 5HT1 FOR ANTIDEPRESSANT THERAPY
EA200300226A1 (en) GEM-SUBSTITUTED ANTAGONISTS INTEGRINE αvβ3